Request Demo
Last update 28 May 2025
BGB-26808
Last update 28 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms BGB 26808, BGB26808 |
Target |
Action inhibitors |
Mechanism HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with BGB-26808NCT05981703
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
100 Clinical Results associated with BGB-26808
Login to view more data
100 Translational Medicine associated with BGB-26808
Login to view more data
100 Patents (Medical) associated with BGB-26808
Login to view more data
100 Deals associated with BGB-26808
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 07 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 07 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 07 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | New Zealand | 07 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free